Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Mesoblast (MESO) announced that it has entered into the Medicaid National Drug Rebate Agreement, NDRA, with the U.S. Centers for Medicare & ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) ...

A new discovery has shed new light on the crucial role of the CD47 protein in bone fracture healing. Scientists have ...

The possibility of gaining access to life-changing stem cell therapy could finally be in reach for many in the region, thanks ...

Nature Cell Co. Ltd. won U.S. FDA breakthrough therapy designation of its autologous adipose-derived mesenchymal stem cell therapy, Jointstem, March 20, becoming the first Korean company to earn the ...

Protara Therapeutics (NASDAQ:TARA – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will ...

The pluripotent and multipotent stem cells are found in the bone marrow, which can differentiate into any tissue in the body.

In the experiment, cells from the dental pulp of mice were exposed to a cytokine called tumor necrosis factor alpha (TNF-α), ...

A transformative study has uncovered the pivotal role of the protein Naked cuticle homolog 2 (NKD2) in regulating the differentiation of bone-forming osteoblasts and bone-resorbing osteoclasts.